Entrada Therapeutics, Inc. (TRDA) Misses Q2 EPS by 22c
Tweet
Share
E-mailGet Alerts TRDA Hot Sheet
Join SI Premium – FREE
Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q2 EPS of ($1.04), $0.22 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $2 million versus the consensus estimate of $9.65 million.
For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi cuts Lowe's price target to $260, keeps Buy rating
- ClearSign Technologies (CLIR) Tops Q2 EPS by 8c
- Autodesk (ADSK) PT Raised to $277 at Guggenheim
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
